November 30, 2016 - By Peter Kolinski
Aegis Capital began its coverage on NuVasive (NASDAQ:NUVA), today 30 November. The broker finds the stock of NUVA attractive and has target price of $72 with Buy rating.
Out of 14 analysts covering Nuvasive Inc. (NASDAQ:NUVA), 12 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 86% are positive. $74 is the highest target while $56 is the lowest. The $65.08 average target is -0.26% below today’s ($65.25) stock price. Nuvasive Inc. has been the topic of 20 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock has “Overweight” rating given by on Monday, October 10. The company was upgraded on Tuesday, October 6 by Canaccord Genuity. JP Morgan upgraded the stock to “Overweight” rating in Wednesday, July 13 report. Northland Capital upgraded it to “Outperform” rating and $68 target price in Thursday, July 30 report. The rating was maintained by Barclays Capital on Wednesday, July 27 with “Overweight”. Jefferies maintained it with “Buy” rating and $72 target price in Wednesday, July 27 report. The stock of NuVasive, Inc. (NASDAQ:NUVA) earned “Outperform” rating by BMO Capital Markets on Tuesday, October 6. The stock has “Neutral” rating given by Bank of America on Friday, December 11. The stock has “Buy” rating given by UBS on Tuesday, September 22. As per Tuesday, September 1, the company rating was maintained by Leerink Swann.
About 43,965 shares traded hands. NuVasive, Inc. (NASDAQ:NUVA) has risen 20.23% since April 27, 2016 and is uptrending. It has outperformed by 15.00% the S&P500.
Analysts await NuVasive, Inc. (NASDAQ:NUVA) to report earnings on February, 9. They expect $0.50 EPS, up 42.86% or $0.15 from last year’s $0.35 per share. NUVA’s profit will be $25.74M for 32.64 P/E if the $0.50 EPS becomes a reality. After $0.40 actual EPS reported by NuVasive, Inc. for the previous quarter, Wall Street now forecasts 25.00% EPS growth.
Insitutional Activity: The institutional sentiment increased to 1.51 in 2016 Q2. Its up 0.40, from 1.11 in 2016Q1. The ratio increased, as 37 funds sold all NuVasive, Inc. shares owned while 77 reduced positions. 45 funds bought stakes while 82 increased positions. They now own 50.84 million shares or 1.81% more from 49.94 million shares in 2016Q1.
Moreover, Shelton Mgmt has 0.02% invested in NuVasive, Inc. (NASDAQ:NUVA) for 4,118 shares. Cap Research Glob Invsts reported 4.47 million shares or 0.09% of all its holdings. Azimuth Capital Management has 0.06% invested in the company for 11,255 shares. Citadel Ltd, a Illinois-based fund reported 167,588 shares. Blue Jay Management Ltd last reported 159,660 shares in the company. Fortaleza Asset Mngmt holds 1,925 shares or 0.09% of its portfolio. Hanseatic Management Services Incorporated holds 12,481 shares or 0.28% of its portfolio. Eam Investors Limited Com holds 0.43% of its portfolio in NuVasive, Inc. (NASDAQ:NUVA) for 47,349 shares. Stephens Grp Ltd Llc has 627,221 shares for 1.23% of their US portfolio. Capstone Asset Mgmt has 0.03% invested in the company for 18,809 shares. Marshall Wace Llp, a United Kingdom-based fund reported 51,294 shares. The Pennsylvania-based Cim Investment Mangement has invested 0.13% in NuVasive, Inc. (NASDAQ:NUVA). Da Davidson & has 1,722 shares for 0% of their US portfolio. Grp One Trading Lp holds 0% or 4,000 shares in its portfolio. Sei Invests holds 94,577 shares or 0.03% of its portfolio.
Insider Transactions: Since June 15, 2016, the stock had 4 buys, and 5 selling transactions for $322,731 net activity. Shares for $170,100 were sold by Hannon Jason on Tuesday, August 23. Another trade for 4,200 shares valued at $244,692 was made by OHALLERAN MICHAEL D on Friday, November 4. The insider HOWE LESLEY H sold $224,909. Stafslien Joan bought $298,400 worth of NuVasive, Inc. (NASDAQ:NUVA) on Monday, October 31. The insider Miles Patrick bought 16,967 shares worth $1.00M.
Nuvasive, Inc. is a medical device company in the spine market. The company has a market cap of $3.35 billion. The Firm focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. It has a 82.81 P/E ratio. The Firm offers two product lines: spine surgery products and biologics.
According to Zacks Investment Research, “NUVASIVE is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company’s product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company’s current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as a growing offering of cervical and motion preservation products.”
Nuvasive, Inc., incorporated on July 21, 1997, is a medical device firm in the spine market. The Firm focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Firm offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The Company’s biologics product line offerings includes allograft (donated human tissue), FormaGraft (a collagen synthetic product), Osteocel Plus and Osteocel Pro (each an allograft cellular matrix containing viable mesenchymal stem cells (MSCs)), and AttraX (a synthetic bone graft material), all of which are used to aid the spinal fusion or bone healing process.
Another recent and important NuVasive, Inc. (NASDAQ:NUVA) news was published by Fool.com which published an article titled: “Weaker Sales Guidance Pushes NuVasive, Inc. Lower by 10%” on October 26, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.